Please login to the form below

Not currently logged in
Email:
Password:

loxapine

This page shows the latest loxapine news and features for those working in and with pharma, biotech and healthcare.

Teva launches first inhaled antipsychotic in US

Teva launches first inhaled antipsychotic in US

Adasuve (loxapine) was originally developed by US company Alexza Pharmaceuticals and becomes the first and only inhaled antipsychotic drug for this indication in the US market. ... According to Teva, the delivery of loxapine using Alexza's proprietary

Latest news

  • EU approves Alexza’s antipsychotic Adasuve EU approves Alexza’s antipsychotic Adasuve

    Company plans to launch it in third quarter of 2013 in partnership with Grupo Ferrer

  • FDA review of Alexza’s Adasuve delayed

    Adasuve (loxapine) is Alexza's lead product and is intended as a more patient-friendly alternative to injectable antipsychotics used to treat agitation in patients with schizophrenia or bipolar mania.

  • FDA panel backs Alexza’s inhaled antipsychotic drug

    Shares in Alexza climbed more than 70 per cent after the 9-8 vote by the Psychopharmacologic Drugs Advisory Committee (PDAC) improved the chances that Adasuve (loxapine delivered using Alexza's ... The speed of onset of treatment with inhaled loxapine is

  • Schizophrenia treatments

    The product uses the Alexza's Staccato hand-held, disposable inhaler technology which vaporises loxapine by heating a thin film of the agent. ... Worldwide revenue projections for inhaled loxapine, cariprazine and TC 5619 are represented in figure 1.

  • Alexza schizophrenia drug delayed

    Alexza said it had completed an end-of-review meeting with the FDA for Adusuve Staccato (loxapine) inhalation aerosol, which is being developed for the rapid treatment of agitation in schizophrenia

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics